BACKGROUND:Allogenic blood transfusion may affect clinical outcomes negatively. Up to 20% of blood transfusions in the United States are associated with cardiac surgery and so strategies to conserve usage are of importance. This study compares administration according to physician's choice based on laboratory coagulation tests with application of a strict protocol based on the thromboelastograph (TEG). METHODS:Sixty-nine patients presenting for cardiac surgery were randomised to either study or control groups. In the study group a strict protocol was followed covering usage of all blood products according to TEG patterns. In the control group, the physician directed product administration with reference to activated partial thromboplastin time (APTT), international normalised ratio (INR), fibrinogen and platelet count. Bleeding, re-sternotomy, minimum haemoglobin, intubation time, and ICU stay were documented. RESULTS: TEG-based management reduced total product usage by 58.8% in the study group but this was not statistically significant. This was associated with a statistically insignificant trend towards better short-term outcomes. CONCLUSIONS: This pilot study suggests that a strict protocol for blood product replacement based on the TEG might be highly effective in reducing usage without impairing short-term outcome.
RCT Entities:
BACKGROUND: Allogenic blood transfusion may affect clinical outcomes negatively. Up to 20% of blood transfusions in the United States are associated with cardiac surgery and so strategies to conserve usage are of importance. This study compares administration according to physician's choice based on laboratory coagulation tests with application of a strict protocol based on the thromboelastograph (TEG). METHODS: Sixty-nine patients presenting for cardiac surgery were randomised to either study or control groups. In the study group a strict protocol was followed covering usage of all blood products according to TEG patterns. In the control group, the physician directed product administration with reference to activated partial thromboplastin time (APTT), international normalised ratio (INR), fibrinogen and platelet count. Bleeding, re-sternotomy, minimum haemoglobin, intubation time, and ICU stay were documented. RESULTS:TEG-based management reduced total product usage by 58.8% in the study group but this was not statistically significant. This was associated with a statistically insignificant trend towards better short-term outcomes. CONCLUSIONS: This pilot study suggests that a strict protocol for blood product replacement based on the TEG might be highly effective in reducing usage without impairing short-term outcome.
Authors: David Jobes; Yanika Wolfe; Daniel O'Neill; Jennifer Calder; Lisa Jones; Deborah Sesok-Pizzini; X Long Zheng Journal: Transfusion Date: 2011-01 Impact factor: 3.157
Authors: Kevin Fleming; Roberta E Redfern; Rebekah L March; Nathan Bobulski; Michael Kuehne; John T Chen; Michael Moront Journal: J Extra Corpor Technol Date: 2017-12
Authors: Alex Gatt; Fabian Bonello; Raphael Buttigieg; Samuel Debono; Patricia Brincat; Charlie Grima; Peter Gatt; Thomas Lofaro; Stefan Laspina Journal: Blood Transfus Date: 2014-06-05 Impact factor: 3.443
Authors: Robert M Judith; Jay K Fisher; Richard Chasen Spero; Briana L Fiser; Adam Turner; Bruce Oberhardt; R M Taylor; Michael R Falvo; Richard Superfine Journal: Lab Chip Date: 2015-03-07 Impact factor: 6.799
Authors: Klaus Görlinger; Dietmar Fries; Daniel Dirkmann; Christian F Weber; Alexander A Hanke; Herbert Schöchl Journal: Transfus Med Hemother Date: 2012-03-08 Impact factor: 3.747
Authors: Elisa A Ferrante; Kiev R Blasier; Thomas B Givens; Cynthia A Lloyd; Timothy J Fischer; Francesco Viola Journal: Anesth Analg Date: 2016-12 Impact factor: 5.108